2013•International Journal of Chemical SciencesRequires access

Validated RP-HPLC Method as a Tool for Simultaneous Estimation of Drotaverine HCL And Mefenamic Acid in Combined Tablet Dosage Form

P. Raghavendra, P M Vasanth, T. Ramesh, Manikandan Ramesh

Open publisher page 0 citations

Abstract

A simple, linear, accurate and precise RP-HPLC method has been developed for the simultaneous estimation of Drotaverine HCl and Mefenamic acid in tablet dosage form. The method was developed on HPLC Waters 2695 using BDS Hypersil C8 Column (100 x 4.6 mm, 5 µ) and the mobile phase of potassium dihydrogen phosphate (pH-2): methanol. Isocratic elution with a flow rate of 1 mL/min was employed at 30o C and the responses were measured at 244 nm by using Waters PDA 2998 detector. The retention times of Drotaverine HCl and Mefenamic acid were found to be 2.033 and 6.659 min. The method shows linearity in the range of 25-75 µg/mL and correlation coefficient was found to be 0.999 for both the drugs. The method was validated as per ICH guidelines and met all specifications including force degradation studies. Statistical studies revealed that the proposed method can be successfully applied for routine analysis of Drotaverine HCl and Mefenamic acid in tablet dosage forms.

About this research paper

What this paper is about

A simple, linear, accurate and precise RP-HPLC method has been developed for the simultaneous estimation of Drotaverine HCl and Mefenamic acid in tablet dosage form. The method was developed on HPLC Waters 2695 using BDS Hypersil C8 Column (100 x 4.6 mm, 5 µ) and the mobile phase of potassium dihydrogen phosphate (pH-2): methanol. Isocratic elution with a flow rate of 1 mL/min was employed at 30o C and the responses were measured at 244 nm by using Waters PDA 2998 detector. The retention times of Drotaverine HCl and Mefenamic acid were found to be 2.033 and 6.659 min. The method shows linearity in the range of 25-75 µg/mL and correlation coefficient was found to be 0.999 for both the drugs. The method was validated as per ICH guidelines and met all specifications including force degradation studies. Statistical studies revealed that the proposed method can be successfully applied for routine analysis of Drotaverine HCl and Mefenamic acid in tablet dosage forms.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A simple, linear, accurate and precise RP-HPLC method has been developed for the simultaneous estimation of Drotaverine HCl and Mefenamic acid in tablet dosage form. The method was developed on HPLC Waters 2695 using BDS Hypersil C8 Column (100 x 4.6 mm, 5 µ) and the mobile phase of potassium dihydrogen phosphate (pH-2): methanol. Isocratic elution with a flow rate of 1 mL/min was employed at 30o C and the responses were measured at 244 nm by using Waters PDA 2998 detector. The retention times of Drotaverine HCl and Mefenamic acid were found to be 2.033 and 6.659 min. The method shows linearity in the range of 25-75 µg/mL and correlation coefficient was found to be 0.999 for both the drugs. The method was validated as per ICH guidelines and met all specifications including force degradation studies. Statistical studies revealed that the proposed method can be successfully applied for routine analysis of Drotaverine HCl and Mefenamic acid in tablet dosage forms.

Key concepts: Mefenamic acid, Chromatography, Dosage form, Chemistry, High-performance liquid chromatography, Correlation coefficient, Potassium, Elution

Related papers

Back to paper searchBrowse research topicsOriginal source
Validated RP-HPLC Method as a Tool for Simultaneous Estimation of Drotaverine HCL And Mefenamic Acid in Combined Tablet Dosage Form — Research Paper | ScholarLens